Opportunity ID: 276385

General Information

Document Type: Grants Notice
Funding Opportunity Number: W81XWH-15-NFRP-IIRA
Funding Opportunity Title: DoD Neurofibromatosis Investigator-Initiated Research Award
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Grant
Category of Funding Activity: Science and Technology and other Research and Development
Category Explanation:
Expected Number of Awards: 7
Assistance Listings: 12.420 — Military Medical Research and Development
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: May 06, 2015
Last Updated Date:
Original Closing Date for Applications: Jul 27, 2015
Current Closing Date for Applications: Jul 27, 2015
Archive Date: Aug 26, 2015
Estimated Total Program Funding: $6,004,000
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility”
Additional Information on Eligibility:

Additional Information

Agency Name: Dept. of the Army — USAMRAA
Description: The NFRP Investigator-Initiated Research Award supports highly rigorous, high-impact research projects that have the potential to make an important contribution to NF research and/or patient care. Research projects may focus on any phase of research, excluding clinical trials. The rationale for a research idea may be derived from laboratory discovery, population-based studies, a clinician’s firsthand knowledge of patients, or anecdotal data. Applications must include preliminary and/or published data that is relevant to NF and the proposed research project.
Preclinical Research: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of preclinical research. The standards are described in Landis, S.C., et al. A call for transparent reporting to optimize the predictive value of preclinical research, Nature 2012, 490:187-191 (www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in research and should be applied. Projects that include research on animal models are required to submit Attachment 8, Animal Research Plan, as part of the application package to describe how these standards will be addressed. Applicants should consult the ARRIVE (Animal Research: Reporting In Vivo Experiments) guidelines to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported. The ARRIVE guidelines can be found at http://www.nc3rs.org.uk/page.asp?id=1357.
Link to Additional Information:
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

CDMRP Help Desk

Phone: 301-682-5507

Email:help@eBRAP.org

Version History

Version Modification Description Updated Date

Folder 276385 Full Announcement-1 -> nfrp_fy15_iira_pa_gg.pdf

Packages

Agency Contact Information: CDMRP Help Desk
Phone: 301-682-5507

Email: help@eBRAP.org

Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
12.420 PKG00216635 May 06, 2015 Jul 27, 2015 View

Package 1

Mandatory forms

276385 RR_SF424_2_0-2.0.pdf

276385 RR_Budget_1_3-1.3.pdf

276385 RR_KeyPersonExpanded_2_0-2.0.pdf

276385 PerformanceSite_2_0-2.0.pdf

Optional forms

276385 RR_SubawardBudget30_1_3-1.3.pdf

2025-07-01T06:42:04-05:00

Share This Post, Choose Your Platform!

About the Author: